Leerink Partnrs Issues Negative Forecast for FDMT Earnings

Key Points

• 4D Molecular Therapeutics has seen its Q3 EPS forecast cut from ($0.88) to ($0.98) by the analyst firm Leerink Partners.
• The company reported a significant loss of ($0.98) EPS for the recent quarter, missing consensus estimates by ($0.10).
• Institutional investors have increased their stakes in 4D Molecular Therapeutics, with 99.27% of the stock owned by hedge funds and other institutional investors.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Stock analysts at Leerink Partnrs dropped their Q3 2025 earnings per share estimates for shares of 4D Molecular Therapeutics in a research note issued on Monday, August 11th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($0.98) per share for the quarter, down from their previous estimate of ($0.88). The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for 4D Molecular Therapeutics' Q4 2025 earnings at ($0.94) EPS, FY2025 earnings at ($3.82) EPS and FY2026 earnings at ($3.79) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.10). The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%.

Other equities analysts have also issued reports about the company. The Goldman Sachs Group dropped their price target on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Chardan Capital reissued a "buy" rating and issued a $25.00 price target on shares of 4D Molecular Therapeutics in a research note on Tuesday, August 12th. Roth Capital dropped their price target on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. Barclays dropped their price target on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Thursday, August 14th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, 4D Molecular Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $30.40.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ:FDMT traded down $0.62 during midday trading on Thursday, reaching $6.65. The company's stock had a trading volume of 630,019 shares, compared to its average volume of 883,681. The firm has a market capitalization of $310.56 million, a price-to-earnings ratio of -1.88 and a beta of 2.83. The firm has a 50 day moving average price of $4.73 and a two-hundred day moving average price of $4.14. 4D Molecular Therapeutics has a fifty-two week low of $2.23 and a fifty-two week high of $17.41.

Institutional Trading of 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd bought a new stake in 4D Molecular Therapeutics during the 1st quarter worth approximately $39,000. Y Intercept Hong Kong Ltd purchased a new position in 4D Molecular Therapeutics in the 1st quarter worth approximately $41,000. Los Angeles Capital Management LLC purchased a new position in 4D Molecular Therapeutics in the 2nd quarter worth approximately $42,000. Quadrature Capital Ltd bought a new position in shares of 4D Molecular Therapeutics in the 2nd quarter worth $42,000. Finally, AQR Capital Management LLC bought a new position in shares of 4D Molecular Therapeutics in the 1st quarter worth $46,000. Institutional investors own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.